Bicentennial Tower lighting up for National Eating Disorders Awareness Week
White Pine Center for Healing is celebrating Eating Disorder Awareness Week in an effort to bring awareness, understanding, and support to a vast majority of community people who experience eating disorders.
Eating disorders have the highest mortality rate of any mental health issue, second to opioid abuse.
'A person in this country dies from an eating disorder every 52 minutes. The top two causes of death are cardiac issues and suicide so these are serious serious mental health issues they're not a choice they're not a lifestyle they are a range of diseases that really affect the entire body,' said Mary Machuga the executive director of White Pine Center for Healing.
The Bicentennial Tower will light up Monday evening at 6:30 p.m.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
USA Today
3 hours ago
- USA Today
Deadly NYC Legionnaires' disease outbreak fueled by negligence, lawsuit says
Civil rights attorney Ben Crump has filed lawsuits against two construction companies over what he called a "completely preventable" outbreak of Legionnaires' disease that has killed five people and sickened more than 100 others in New York City. Legionnaires' disease is a severe pneumonia caused by a type of bacteria called Legionella, which grows in warm or hot water, according to the Centers for Disease Control and Prevention. An outbreak of the disease, which began on July 25, has been clustered across five zip codes in Central Harlem. The city health department said the outbreak is linked to cooling towers, heat exchangers that use fans and water to cool down buildings. On Aug. 14, health officials confirmed that 12 cooling towers at buildings including NYC Health + Hospitals/Harlem tested positive for the Legionella bacteria. Crump and other attorneys filed complaints on behalf of two construction workers who were hospitalized with Legionnaire's disease in July after working near the hospital in Harlem, according to a news release. Crump said the legal team has also filed a notice of claim and intend to sue the city as well. "It is believed that the cooling towers at Harlem Hospital were filled with rainwater after several large July storms," the release said. "The water was left untreated, which permitted bacteria to spread causing workers at the site to become sick." Construction companies, city accused of negligence Crump accused Skanska USA Building, Inc., Rising Sun Construction LLC and the city of negligence at a news conference on Aug. 20, announcing the lawsuits. The attorneys said the construction companies were put on notice about the possibility of Legionella bacteria through bulletins after the storms, but failed to take action to keep those working near the hospital safe. "When corporations cut corners, tragedies like this happen. Preventable tragedies, unnecessary tragedies," Crump said. Crump said the lawsuit is seeking not only compensation for the workers but also accountability and answers about why this outbreak occurred in Harlem — a historically Black neighborhood in Upper Manhattan. Skanska and Rising Sun did not immediatedly respond to a request for comment from USA TODAY. When asked about Crump's claims about the source of the outbreak, a spokesperson for the city's health department said the investigation is ongoing. "Molecular testing may help us determine which cooling tower — or cooling towers — were the source of the bacteria in the Central Harlem cluster," spokesperson Chantal Gomez said in a statement. "The Public Health Lab is still determining a match through DNA sequencing and we expect final results soon.' Electrian describes gasping for air while hospitalized with Legionnaire's Nunzio Quinto, a union electrian who worked at a ground-up construction of the NewYork City Public Health Laboratory, a 10-story facility adjacent to the hospital complex, said he thought he had food poisoning when he first started feeling lethargic in late July. Quinto said his family took him to the hospital, where he was immediately diagnosed with Legionnaire's disease. He suffered breathing problems, pain and internal bleeding during a five-day stay in the hospital, but said his coworkers weren't notified of his illness. "I want answers to what's going on. I can't have a safe place to work? This is New York City," Quinto said at the news conference. Contributing: Thao Nguyen
Yahoo
4 hours ago
- Yahoo
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the biotechnology company's vaccines. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology. The Maryland-based company has an approved COVID-19 vaccine, Nuvaxovid, which is being commercialized globally through partnerships, including a major agreement with Sanofi. Currently, the company is expanding its product reach for emerging infectious disease prevention. On May 19, 2025, Novavax, Inc. (NASDAQ:NVAX) announced that it had received U.S. FDA Biologics License Application (BLA) approval for Nuvaxovid™, a recombinant protein-based, non-mRNA COVID-19 vaccine. The BLA approval triggered a $175 million milestone payment from Sanofi. Later, for select markets, Novavax, Inc. (NASDAQ:NVAX) has completed the transition of Nuvaxovid™ commercial leadership to Sanofi for the 2025-2026 COVID-19 vaccination season. By Q4 2025, the marketing authorization transfers to Sanofi for the U.S. and EU markets will be completed, which will result in an additional $50 million in combined milestones. Additionally, in June 2025, initial cohort data from a Phase 3 trial for Novavax's COVID-19-Influenza-Combination (CIC) and stand-alone influenza vaccine candidates showed significant immune responses, with T-cell responses numerically higher than the comparator Fluzone HD arm. With the results suggesting increased duration of protection, the company is discussing potential partnerships for these late-stage assets. Novavax, Inc. (NASDAQ:NVAX)'s 29.12% short float signals heavy bearish sentiment. With it, the company is up on the stage for a sharp rebound with slight positive market sentiment shifts. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
